A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.